individuals who indicate they have no chronic health condition. Results are compared using mean errors (ME), root mean squared errors (RMSE) and the proportion of values estimated within |0.05|. RESULTS: Using an age adjusted baseline, we found the additive (and multiplicative) methods underestimate the majority of HSUVs (ME:0.0781(0.0254); RMSE:0.1012(0.0651); 26%(56%) < |0.05|) while the minimum (and ADE) overestimate the majority of HSUVs (ME:−0.0995(−0.0695); RMSE:0.1214(0.0950); 20%(35%) < |0.05|). Although the simple linear model produced the most accurate results (ME:0.0001; RMSE:0.0598; 63% < |0.05|), there were some substantial errors with 20% of errors greater than the minimum important difference (|0.074|). When subgrouping by actual HSUV (range 0.350-0.917) we found the magnitude and direction of errors in the estimated HSUVs are driven by the actual HSUVs being estimated in addition to the technique used. In general the HSUVs estimated using an adjusted baseline were more accurate than those obtained using a baseline of perfect health. CONCLUSIONS: This study makes an important contribution to the evidence in this area as it is the fi rst to compare the fi ve different techniques in the same data set. While the simple linear model gave the most accurate results, the model requires validating in external data and additional research exploring an alternative model specifi cation is warranted.
PMC35 RECOMMENDATIONS ABOUT TRANSLATIONS IN THE FINAL FDA GUIDANCE ON PRO MEASURES: WHAT HAS CHANGED AND WHAT HAS REMAINED
Conway K 1 , Mear I 2 1 MAPI Research Trust, Lyon, France; 2 MAPI Institute, Lyon, France OBJECTIVES: Almost four years were necessary to develop the fi nal FDA guidance on the use of PRO measures in clinical trials. Our objective is to compare how the recommendations about translation and cultural adaptation evolved from the 2006 draft to the 2009 fi nal guidance. METHODS: Both guidances were retrieved on the FDA website and analyzed. RESULTS: Structure and content were modifi ed. Recommendations on translation and cultural adaptation were moved to another section within the Evaluating PRO Instruments Part: from "IV.D. Modifi cation of an existing instrument" to "III.G. PRO Instruments intended for specifi c populations". As for the content, the text in the body of the fi nal guidance is more concise compared to the draft. The novelty lies in the stipulation that the FDA will review the process used to translate/culturally adapt the instruments. As a consequence, an appendix (section VIII) was added in which the FDA explains which topics should be addressed in the documents provided to the FDA for review: description of process used, patient testing, rationale for decisions, copies of versions and evidence about validity. They are however key points which did not change: the need for providing evidence that content validity and other measurement properties are similar between all versions. CONCLUSIONS: The recommendations are more concise and precise, especially the expectations of the FDA. The FDA however does not indicate a preference for a specifi c translation methodology. Interestingly patient testing is clearly indicated as a key point of the process. The need for documenting all decisions is crucial and raises the question of developing standardized system of reporting to structure the evidence to be provided to the FDA. The last point of the Appendix is debatable as we anticipate that it might add a burden in term of costs to provide evidence about the psychometrics of all versions.
PMC36 SYSTEMATIC REVIEW OF THE RESPONSIVNESS OF SF-36 HEALTH SURVEY MEASURES TO EFFICACIOUS PHARMACEUTICAL THERAPIES IN WELL-CONTROLLED CLINICAL TRIALS
Ware JE, Frendl DM University of Massachusetts, Worcester, MA, USA OBJECTIVES: To determine how often SF-36 Health Survey measures respond to effi cacious pharmaceutical treatment benefi ts in well-controlled clinical trials.
METHODS:
We conducted a systematic review of randomized, double-blind, placebocontrolled trials published in 124 journals in 1995 through 2009 documenting differences between treatment groups for primary medical endpoints and any of the SF-36 component summaries, or eight subscale scores. Concordance was defi ned in terms of agreement between primary clinical and SF-36 endpoints (both statistically signifi cant or both non-signifi cant). RESULTS: A review of 2,020 identifi ed clinical trials using the SF-36 confi rmed that 162 met study design criteria. For 133 of 162 trials (82.1%), results for primary clinical endpoints and SF-36 measures were concordant. Among the 107 trials achieving medical effi cacy (primary endpoint), changes in one or more SF-36 measures were also signifi cant, as hypothesized, for 88 (82.2%). Similar patterns were observed by therapeutic area; for example: rheumatology (29 of 30), neurology (16 of 25), cardiovascular (15 of 18), pulmonary (11 of 13), psychiatry (8 of 10), endocrine (7 of 9), and combined surgical specialties (9 of 9) studies demonstrated concordance. In addition to evaluating characteristics of published reports and scoring methods (subscales, summaries, utility scoring) this presentation will comment on priorities for future studies of patient-reported outcomes (PROs) in evaluations of pharmaceutical and other medical treatments. CONCLUSIONS: In support of their validity as PROs, changes in SF-36 measurements agree with primary endpoints in over 8 out of 10 well-controlled trials of pharmaceutical therapies published to date. In support of pharmaceuticals' effi cacy, when a therapy positively impacted clinical endpoints, it also improved health related quality of life quality of life in over 8 out of 10 clinical trials published to date.
PMC37 DOES DATA COLLECTION FROM ONLINE COMMUNITIES RESULT IN BIASED RESPONSE?
Vaccarino AL 1 , Sills TL 1 , Bharmal M 2 , Cascade E 3 , Kalali AH 4 , Evans KR 1 1 OCBN, Toronto, ON, Canada; 2 Quintiles, Rockville, MD, USA; 3 iGUARD Inc, Rockville, MD, USA; 4 Quintiles CNS Therapeutics, San Diego, CA, USA OBJECTIVES: Although the ability to interact with patients in an on-line environment has expanded substantially over the past few years, many researchers are concerned that participants may not be representative from a medication experience perspective (i.e., biased towards complainers). The purpose of this study is to investigate patient responses on treatment satisfaction using a validated PRO measure, the Treatment Satisfaction Questionnaire for Medications (TSQM), collected through a survey of patients with depression from an on-line community. METHODS: A random sample of iGuard.org members treated with an antidepressant were invited to complete an online version of the TSQM, a widely used validated 14-item generic treatment satisfaction instrument. iGuard.org is an online patient community that provides a free medication monitoring service to patients. Non-parametric item response analyses were performed to determine the relationship between scores on individual items and total TSQM scores. RESULTS: Responses from 3641 patients were included in the analyses. TSQM Global Satisfaction scores ranged from 0-100 suggesting a broad spectrum of treatment satisfaction. Non-parametric Item Response analyses of raw scores revealed that individual items of the TSQM discriminated differences in patient satisfaction. That is, as total scores increased the probability of low scores on the individual items decreased and the probability of higher scores increased. As expected, patient satisfaction was related to reported side-effects, with those reporting sideeffects experiencing lower satisfaction with medication than those without reported side-effects. CONCLUSIONS: The results from this analysis suggest that PRO survey data collected through a random sample of members of the on-line patient community iGuard.org can be representative of the spectrum of anticipated treatment satisfaction responses. Continuing to explore the potential of direct data capture from on-line patients will be important as researchers seek faster and cheaper alternatives to traditional physician-based recruitment.
PMC38 A COGNITIVE DEBRIEFING METHODOLOGY FOR ESTABLISHING EQUIVALENCE DURING E-PRO MIGRATION
Doyle S, Wild D Oxford Outcomes Ltd, Oxford, Oxon, UK BACKGROUND: Most outcomes instruments have been developed and validated as paper versions, but few have been migrated to electronic format. Migration to electronic delivery, without signifi cantly altering format or text, qualifi es as a minor modifi cation not requiring a full validation (Coons et al. 2009 ). However, this does not mean that the two formats are perceived in the same way by patients. We aim here to describe a methodology successfully used to establish equivalence between paper and electronic PROs. METHODS: To demonstrate the equality of these different modes of data collection, we have used a combination of "think-aloud" and retrospective cognitive debriefi ng techniques, as well as usability testing. The debriefi ng exercise is designed to assess whether the electronic device changes the way respondents interpret the questions or response options. The usability testing assesses ease of use and identifi es issues that may prohibit the use of the ePRO by the target
